Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - substance use disorder and psychotic disorder

Creative Commons License

ERDOĞAN A., KULAKSIZOĞLU B., BİNGÖL M. S., CİNEMRE B., Kuloglu M. M.

Dusunen Adam - The Journal of Psychiatry and Neurological Sciences, cilt.34, sa.1, ss.102-106, 2021 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.14744/dajpns.2021.00126
  • Dergi Adı: Dusunen Adam - The Journal of Psychiatry and Neurological Sciences
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Psycinfo, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.102-106
  • Anahtar Kelimeler: Craving, long-acting injectable aripiprazole, substance-induced psychotic disorder, treatment
  • Akdeniz Üniversitesi Adresli: Evet

Özet

© 2021 Yerkure Tanitim ve Yayincilik Hizmetleri A.S.. All rights reserved.In recent years, the rate of substance-induced psychotic disorder (SIPD) has been gradually increasing. Non-compliance with treatment and substance craving are serious problems in SIPD. Novel depot antipsychotic treatments, such as long-acting injectable aripiprazole monohydrate 400 mg (LAIAM) are reported to improve treatment compliance and functionality in psychotic disorders. However, the number of studies showing the efficacy of LAIAM treatment in patients with dual diagnosis is limited. In this paper, we present two cases. The first case was diagnosed with SIPD and the other was diagnosed with psychotic disorder with a past history of profound substance use disorder. The two cases showed both clinical and functional improvement at 1-year follow-up after the initiation of LAIAM treatment. These case reports suggest that LAIAM treatment might be an effective and safe treatment option in SIPD and reduce substance craving.